Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3548-3555

  Jullien, Vincent ^a,b,c,e   Urien, Saïk ^f,j   Hirt, Déborah ^a,c,e   Delaugerre, Constance ^a,b,g,i   Rey, Elisabeth ^a,b,c,e   Teglas, Jean Paul ^f   Vaz, Paula ^a,b,h,i   Rouzioux, Christine ^a,b,g,i   Chaix, Marie Laure ^a,b,g,i   Macassa, Eugenia ^a,b,h,i   Firtion, Ghislaine ^b,d,e   Pons, Gérard ^a,b,c,e   Blanche, Stéphane ^a,b,h,i   Tréluyer, Jean Marc ^a,b,c,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Pharmacologie Clinique   (France)

^d Service de Gynecologie Obstetrique   (France)

^e Groupe Hospitalier Cochin Saint Vincent de Paul ^*  (France)

^f INSERM   (France)

^g Virology   (France)

^h Unité d'Immunologie Hématologie Pédiatrique   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j CENTRE RENÉ HUGUENIN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; NEVIRAPINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONLINEAR SYSTEM; PLASMA CLEARANCE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; AGE FACTORS; ALGORITHMS; ANTI-HIV AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; POPULATION; PYRIMIDINONES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEX FACTORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33750594232     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00943-05     Document Type: Article

References (31)

1. Beal, S. L., and L. B. Sheiner. 1991. NONMEM user's guide. NONMEM Project Group, University of California at San Francisco, San Francisco, Calif.
2. Benet, L. Z., and B. A. Hoener. 2002. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71:115-121.
3. Bergshoeff, A. S., P. L. Fraaij, J. Ndagijimana, G. Verweel, N. G. Hartwig, T. Niehues, R. De Groot, and D. M. Burger. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J. Acquir. Immune Defic. Syndr. 39:63-68.
4. Blake, M. J., L. Castro, J. S. Leeder, and G. L. Kearns. 2005. Ontogeny of drug metabolizing enzymes in the neonate. Semin. Fetal Neonatal Med. 10:123-138.
5. Boffito, M., P. G. Hoggard, W. E. Lindup, S. Bonora, A. Sinicco, S. H. Khoo, G. Di Perri, and D. J. Back. 2004. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther. Drug Monit. 26:35-39.
6. Breilh, D., I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, H. Budzinski, M. Munck, H. J. Fleury, M. C. Saux, and J. L. Pellegrin. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310.
7. Burger, D. M., A. M. van Rossum, P. W. Hugen, M. H. Suur, N. G. Hartwig, S. P. Geelen, H. J. Scherpbier, R. M. Hoetelmans, A. G. Vulto, and R. de Groot. 2001. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. 45:701-705.
8. Cotreau, M. M., L. L. von Moltke, and D. J. Greenblatt 2005. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet 44:33-60.
9. Crommentuyn, K. M., B. S. Kappelhoff, J. W. Mulder, A. T. Mairuhu, E. C. van Gorp, P. L. Meenhorst, A. D. Huitema, and J. H. Beijnen. 2005. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60:378-389.
10. Csajka, C., C. Marzolini, K. Fattiuger, L. A. Decosterd, A. Telenti, J. Biollaz, and T. Buclin. 2004. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:3226-3232.
11. Delaugerre, C., J. P. Teglas, J. M. Treluyer, P. Vaz, V. Jullien, F. Veber, C. Rouzioux, M. L. Chaix, and S. Blanche. 2004. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 37:1269-1275.
12. Gatti, G., A. Vigano, N. Sala, S. Vella, M. Bassetti, D. Bassetti, and N. Principi. 2000. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 44:752-755.
13. Grub, S., P. Delora, E. Ludin, F. Duff, C. V. Fletcher, R. C. Brundage, M. W. Kline, N. R. Calles, H. Schwarzwald, and K. Jorga. 2002. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 71:122-130.
14. Hsu, A., G. R. Granneman, and R. J. Bertz. 1998. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35:275-291.
15. Hurst, M., and D. Faulds. 2000. Lopinavir. Drugs 60:1371-1379.
16. Itoh, S., T. Yanagimoto, S. Tagawa, H. Hashimoto, R. Kitamura, Y. Nakajima, T. Okochi, S. Fujimoto, J. Uchino, and T. Kamataki. 1992. Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5′ flanking region. Biochim. Biophys. Acta 1130:133-138.
17. Kappelhoff, B. S., K. M. Crommentuyn, M. M. de Maat, J. W. Mulder, A. D. Huitema, and J. H. Beijnen. 2004. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43:845-853.
18. Kearns, G. L., S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167.
19. Kline, M. W., R. C. Brundage, C. V. Fletcher, H. Schwarzwald, N. R. Calles, N. E. Buss, P. Snell, P. DeLora, M. Eason, K. Jorga, C. Craig, and F. Duff. 2001. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 20:666-671.
20. Lambert, G. H., D. A. Schoeller, A. N. Kotake, C. Flores, and D. Hay. 1986. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev. Pharmacol. Ther. 9:375-388.
21. Marcelin, A. G., I. Cohen-Codar, M. S. King, P. Colson, E. Guillevic, D. Descamps, C. Lamotte, V. Schneider, J. Ritter, M. Segondy, H. Peigue-Lafeuille, L. Morand-Joubert, A. Schmuck, A. Ruffault, P. Palmer, M. L. Chaix, V. Mackiewicz, V. Brodard, J. Izopet, J. Cottalorda, E. Kohli, J. P. Chauvin, D. J. Kempf, G. Peytavin, and V. Calvez. 2005. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 49:1720-1726.
22. Mazoit, J. X., and B. J. Dalens. 2004. Pharmacokinetics of local anaesthetics in infants and children. Clin. Pharmacokinet. 43:17-32.
23. Mueller, B. U., R. P. Nelson, Jr., J. Sleasman, J. Zuckerman, M. Heath-Chiozzi, S. M. Steinberg, F. M. Balis, P. Brouwers, A. Hsu, R. Saulis, S. Sei, L. V. Wood, S. Zeichner, T. T. Katz, C. Higham, D. Aker, M. Edgerly, P. Jarosinski, L. Serchuck, S. M. Whitcup, D. Pizzuti, and P. A. Pizzo. 1998. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 101:335-343.
24. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
25. Ribera, E., R. M. Lopez, M. Diaz, L. Pou, L. Ruiz, V. Falco, M. Crespo, C. Azuaje, I. Ruiz, I. Ocana, B. Clotet, and A. Pahissa. 2004. Steady-state phaimacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4256-4262.
26. Rogol, A. D. 2004. Gender and hormonal regulation of growth. J. Pediatr. Endocrinol. Metab. 17(Suppl. 4):1259-1265.
27. Saez-Llorens, X., A. Violari, C. O. Deetz, R. A. Rode, P. Gomez, E. Handelsman, S. Pelton, O. Ramilo, P. Cahn, E. Chadwick, V. Allen, S. Arpadi, M. M. Castrejon, R. S. Heuser, D. J. Kempf, R. J. Bertz, A. F. Hsu, B. Bernstein, C. L. Renz, and E. Sun. 2003. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22:216-224.
28. Schwartz, J. B. 2003. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42:107-121.
29. Taburet, A. M., G. Raguin, C. Le Tiec, C. Droz, A. Barrail, I. Vincent, L. Morand-Joubert, G. Chene, F. Clavel, and P. M. Girard. 2004. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 75:310-323.
30. Veldhuis, J. D., J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers. 2005. Endocrine control of body composition in infancy, childhood, and puberty. Endocrine Rev. 26:114-146.
31. Wijnand, H. P. 1988. Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal. J. Pharmacokinet. Biopharm. 16:109-128.